Gender: Male
|
117 (49)
|
55 (53)
|
62 (45)
|
0.24
|
Age, years
|
9.1 (7.2-11.1)
|
8.9 (6.1-11.1)
|
9.4 (7.6-11.2)
|
0.046
|
Prior to initiate NNRTI regimen
|
CDC clinical staging
| | | |
0.04
|
N
|
10 (4.2)
|
7 (6.7)
|
3 (2.2)
| |
A
|
58 (24.3)
|
29 (27.9)
|
29 (21.6)
| |
B
|
113 (47.3)
|
39 (37.5)
|
74 (54.8)
| |
C
|
58 (24.3)
|
29 (27.9)
|
29 (21.5)
| |
CD4 percentage
|
5 (1–10)
|
3.5 (1–11)
|
5 (2–10)
|
0.53
|
CD4 cell/mm3
|
109 (27–410)
|
109 (21–395)
|
112 (28–413)
|
0.51
|
Prior to switch to second-line boosted -PI regimen
|
Weight for age Z-score
|
−1.7 (−2.1 to −0.9)
|
−1.4 (−1.9 to −0.7)
|
−1.9 (−2.3 to −1.4)
|
<0.001
|
CD4% (n = 239)
|
10 (4–18)
|
17 (7–24)
|
6 (2–12)
|
<0.001
|
CD4 cell/mm3 (n = 238)
|
195 (70–442)
|
379 (165–659)
|
123 (38–273)
|
<0.001
|
HIV RNA, log 10 copies/mL (n = 227)
|
4.8 (4.3-5.3)
|
4.5 (3.9-5.1)
|
4.9 (4.5-5.4)
|
<0.001
|
Antiretroviral treatment history
|
Mono/dual NRTI exposure prior to NNRTI-based regimen
|
71 (29.5)
|
23 (22.1)
|
48 (35.0)
|
0.03
|
Duration on NNRTI-based treatment, years
|
2.2 (1.5-2.9)
|
2.3 (1.5-3.1)
|
2.0 (1.4-2.9)
|
0.04
|
NNRTI regimen
| | | |
0.01
|
Nevirapine
|
167 (69.3)
|
81 (77.9)
|
86 (62.8)
| |
Efavirenz
|
74 (30.7)
|
23 (22.1)
|
51 (37.2)
| |
NRTI-backbone
| | | | |
d4T/3TC
|
142(58.9)
|
71 (68.2)
|
71 (51.8)
|
0.015
|
AZT/3TC
|
60 (24.9)
|
25(24.0)
|
35(25.6)
| |
d4T/ddI
|
17 (7.1)
|
4 (3.9)
|
13(9.5)
| |
AZT/ddI
|
14(5.8)
|
3(2.9)
|
11(8.0)
| |
ddI/3TC
|
8 (3.3)
|
1 (1.0)
|
7 (5.1)
| |
Multi-NRTI resistance2
| | | |
<0.001
|
No TAMs
|
45/203(22.2)
|
38/89 (42.7)
|
7/114 (6.1)
| |
Low grade multi-NRTI
|
78/203 (38.4)
|
40/89 (44.9)
|
38/114 (33.3)
| |
High grade multi-NRTI
|
80/203 (39.4)
|
11/89 (12.4)
|
69/114 (60.5)
| |